Jinxin Fertility Group Limited
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. It offers two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF … Read more
Jinxin Fertility Group Limited (JXFGF) - Net Assets
Latest net assets as of June 2025: $9.25 Billion USD
Based on the latest financial reports, Jinxin Fertility Group Limited (JXFGF) has net assets worth $9.25 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($14.01 Billion) and total liabilities ($4.76 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.25 Billion |
| % of Total Assets | 66.05% |
| Annual Growth Rate | 78.48% |
| 5-Year Change | 38.75% |
| 10-Year Change | N/A |
| Growth Volatility | 405.58 |
Jinxin Fertility Group Limited - Net Assets Trend (2016–2024)
This chart illustrates how Jinxin Fertility Group Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jinxin Fertility Group Limited (2016–2024)
The table below shows the annual net assets of Jinxin Fertility Group Limited from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $10.35 Billion | +1.64% |
| 2023-12-31 | $10.19 Billion | +16.62% |
| 2022-12-31 | $8.74 Billion | -0.20% |
| 2021-12-31 | $8.75 Billion | +17.29% |
| 2020-12-31 | $7.46 Billion | -2.35% |
| 2019-12-31 | $7.64 Billion | +69.84% |
| 2018-12-31 | $4.50 Billion | +230.47% |
| 2017-12-31 | $1.36 Billion | +1253.92% |
| 2016-12-31 | $100.57 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jinxin Fertility Group Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 8902.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.71 Billion | 16.65% |
| Common Stock | $182.00K | 0.00% |
| Other Components | $8.56 Billion | 83.35% |
| Total Equity | $10.27 Billion | 100.00% |
Jinxin Fertility Group Limited Competitors by Market Cap
The table below lists competitors of Jinxin Fertility Group Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Orrstown Financial Services Inc
NASDAQ:ORRF
|
$590.37 Million |
|
Devyani International Limited
NSE:DEVYANI
|
$590.49 Million |
|
CTO Realty Growth Inc
NYSE:CTO
|
$590.56 Million |
|
Shiny Chemical Industrial Co Ltd
TW:1773
|
$590.61 Million |
|
F.C.C. Co. Ltd
F:FCV
|
$590.17 Million |
|
Dios Fastigheter AB
ST:DIOS
|
$590.09 Million |
|
Hebei Huijin Electromechanical Co Ltd
SHE:300368
|
$589.87 Million |
|
NanJi ECommerce Co Ltd
SHE:002127
|
$589.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jinxin Fertility Group Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 10,091,423,000 to 10,274,419,000, a change of 182,996,000 (1.8%).
- Net income of 283,099,000 contributed positively to equity growth.
- Dividend payments of 150,000,000 reduced retained earnings.
- Share repurchases of 51,313,000 reduced equity.
- Other comprehensive income increased equity by 392,005,000.
- Other factors decreased equity by 290,795,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $283.10 Million | +2.76% |
| Dividends Paid | $150.00 Million | -1.46% |
| Share Repurchases | $51.31 Million | -0.5% |
| Other Comprehensive Income | $392.00 Million | +3.82% |
| Other Changes | $-290.80 Million | -2.83% |
| Total Change | $- | 1.81% |
Book Value vs Market Value Analysis
This analysis compares Jinxin Fertility Group Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.07x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 8.42x to 0.07x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $0.03 | $0.28 | x |
| 2017-12-31 | $0.39 | $0.28 | x |
| 2018-12-31 | $1.83 | $0.28 | x |
| 2019-12-31 | $3.41 | $0.28 | x |
| 2020-12-31 | $3.01 | $0.28 | x |
| 2021-12-31 | $3.41 | $0.28 | x |
| 2022-12-31 | $3.29 | $0.28 | x |
| 2023-12-31 | $3.69 | $0.28 | x |
| 2024-12-31 | $3.78 | $0.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jinxin Fertility Group Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.07%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.46x
- Recent ROE (2.76%) is below the historical average (16.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 110.58% | 25.28% | 0.46x | 9.54x | $79.66 Million |
| 2017 | 10.65% | 14.90% | 0.38x | 1.87x | $6.00 Million |
| 2018 | 3.82% | 18.07% | 0.14x | 1.50x | $-269.72 Million |
| 2019 | 5.44% | 24.85% | 0.18x | 1.19x | $-343.07 Million |
| 2020 | 3.45% | 17.64% | 0.16x | 1.26x | $-476.68 Million |
| 2021 | 3.98% | 18.48% | 0.14x | 1.50x | $-514.63 Million |
| 2022 | 1.40% | 5.12% | 0.16x | 1.76x | $-742.85 Million |
| 2023 | 3.42% | 12.36% | 0.19x | 1.48x | $-664.42 Million |
| 2024 | 2.76% | 10.07% | 0.19x | 1.46x | $-744.34 Million |
Industry Comparison
This section compares Jinxin Fertility Group Limited's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $250,407,165
- Average return on equity (ROE) among peers: -38.80%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jinxin Fertility Group Limited (JXFGF) | $9.25 Billion | 110.58% | 0.51x | $590.21 Million |
| Addus HomeCare Corporation (ADUS) | $113.86 Million | 16.82% | 0.44x | $1.75 Billion |
| agilon health Inc (AGL) | $126.73 Million | -319.84% | 9.03x | $166.17 Million |
| Airsculpt Technologies Inc (AIRS) | $123.68 Million | 6.13% | 0.45x | $16.62 Million |
| Amedisys Inc (AMED) | $454.23 Million | -18.40% | 0.61x | $3.26 Billion |
| AMN Healthcare Services Inc (AMN) | $347.86 Million | 23.54% | 1.53x | $624.22 Million |
| American Shared Hospital Service (AMS) | $20.85 Million | 8.48% | 1.33x | $7.93 Million |
| American Oncology Network Inc. (AONC) | $226.04 Million | -0.05% | 0.10x | $112.23 Million |
| Ardent Health Partners, Inc. (ARDT) | $1.08 Billion | 4.65% | 3.71x | $225.22 Million |
| Arem Pacific Corporation (ARPC) | $-45.09K | 0.00% | 0.00x | $246.12K |
| Astrana Health Inc (ASTH) | $8.55 Million | -109.27% | 1.29x | $1.08 Billion |